From development to manufacturing: ensuring quality and functionality in gene therapy
Sponsor
.png "https://www.bio-techne.com/instruments"){kind=logo}
Live30 webinars are thirty-minute presentations designed to update you on the latest innovations, applications, and data in a fast yet interactive format.
Achieving safe and effective transgene delivery is among the greatest challenges faced by gene therapy developers. The inherent complexity of viral vectors makes them difficult to characterize with consistency throughout development and manufacturing stages. One solution is leveraging automated solutions for quantitative viral characterization.
In this webinar, we will discuss precision analytical tools for critical quality attribute analysis to ensure safe, high quality, consistent, and efficacious therapies. We will present new data on Simple Plex, capillary electrophoresis and Simple Western techniques for analyzing capsid titer, VP3 deamidation, and relative potency in the viral vector-based gene therapy development workflow.
- How to achieve rapid titer assessments using Simplex Plex technology
- How to harness imaged capillary electrophoresis for GMP-grade vector stability assessment and CE-SDS for capsid protein ratios and purity
- The advantages of protein expression potency assays with automated Simple Western platforms
SPEAKERS
You might also like
From concept to clinic: overcoming the challenges of potency assays in cell and gene therapy development
Optimizing access to high quality, standardized, and compliant leukopaks for the development and commercialization of allogeneic therapies
Analytical strategies for sterility and mycoplasma testing in biotherapies: from early development to production scale-up
